`
`———————————
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`———————————
`
`REGENERON PHARMACEUTICALS, INC.
`
`Petitioner,
`
`v.
`
`NOVARTIS PHARMA AG,
`NOVARTIS TECHNOLOGY LLC,
`NOVARTIS PHARMACEUTICALS CORPORATION,
`
`Patent Owners.
`
`
`———————————
`
`
`Patent Number: 9,220,631
`
`
`———————————
`
`
`DECLARATION OF DR. SZILÁRD KISS
`
`
`
`
`
`Regeneron Exhibit 1093.001
`
`
`
`
`
`1.
`
`I have been retained by Petitioner Regeneron Pharmaceuticals, Inc.
`
`(“Petitioner” or “Regeneron”), as an independent expert witness in the above-
`
`captioned inter partes review (“IPR”), in which Regeneron has requested that the
`
`U.S. Patent and Trademark Office cancel as unpatentable all claims of U.S. Patent
`
`No. 9,220,631 (“the ’631 patent”).
`
`2. My qualifications and compensation are set forth in my original
`
`declaration submitted with Regeneron’s Petition for Inter Partes Review. See Ex.
`
`1031 (Kiss Decl.) at ¶¶ 4-12.
`
`3.
`
`I have provided this supplemental declaration to authenticate two
`
`exhibits, Exhibits 1058 and 1059, which are cited in my original declaration, and
`
`for which I understand the Patent Owner has submitted objections. See Paper 17
`
`(Patent Owner Objections).
`
`4.
`
`Exhibit 1058 is an abstract I reviewed in forming my opinions set
`
`forth in my original declaration (Ex. 1031). The citation for the abstract is:
`
`Christine I. Falkner-Radler, et al., Needle Size in Intravitreal Injections-
`
`Preliminary Results of a Randomized Clinical Trial, AVRO Annual Meeting
`
`Abstract, March 2012, 54(884), available at
`
`https://iovs.arvojournals.org/article.aspx?articleid=2350271.
`
`5.
`
`Exhibit 1058 was published by Investigative Ophthalmology & Visual
`
`Science, which is a peer-reviewed official journal of the Association for Research
`
`1
`
`Regeneron Exhibit 1093.002
`
`
`
`
`
`in Vision and Ophthalmology (ARVO). I have personally reviewed the abstract
`
`and confirm that Exhibit 1058 is a copy of the abstract that is accessible via the
`
`above url.
`
`6.
`
`Exhibit 1059 is an article I reviewed in forming my opinions set forth
`
`in my original declaration (Ex. 1031). The citation for the article is: Carsten H.
`
`Meyer, et al., Steps for a Safe Intravitreal Injection Technique – A look at how
`
`European and American approaches compare, Retinal Physician (July 1, 2009),
`
`available at https://www.retinalphysician.com/issues/2009/july-aug/steps-for-a-
`
`safe-intravitreal-injection-technique.
`
`7.
`
`Exhibit 1059 was published in Retinal Physician, a comprehensive
`
`retinal care journal. The journal is frequently read, relied upon, and cited by retinal
`
`surgeons such as myself, as well by ophthalmologists generally. I have personally
`
`reviewed the article and confirm that Exhibit 1059 is a copy of the article available
`
`in the archive of the Retinal Physician website.
`
`8.
`
`I declare that all statements made herein of my own knowledge are
`
`true and that all statements made on information and belief are believed to be true;
`
`and further that these statements were made with the knowledge that willful false
`
`statements and the like so made are punishable by fine or imprisonment, or both,
`
`under Section 1001 of Title 18 of the United States Code.
`
`
`
`
`
`
`2
`
`Regeneron Exhibit 1093.003
`
`
`
`
`
`
`Dated: ___________________
`
`
`
`
`
`
`
`By: _________________________
`
`Dr. Szilárd Kiss
`
`
`
`
`
`3
`
`November 22, 2021
`
`Regeneron Exhibit 1093.004
`
`